Acquirers Announce Mandatory Open Offer for Parmax Pharma Ltd Stocks
A consortium of individuals, led by Dhiren Chandulal Shah and Sunil Chinubhai Shah, has launched a mandatory Open Offer to acquire up to 23,46,250 Equity Shares in Parmax Pharma Limited. The offer aims to secure a substantial stake in the pharmaceutical company, with Acquirers and their associated Persons Acting in Concert (PACs) projected to hold a significant portion of the expanded voting capital upon completion.The Open Offer is being made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten designated PACs. The offer aims to acquire up to 23,46,250 fully paid-up Equity Shares of Parmax Pharma Limited (the "Target Company"). These shares represent 26.00% of the Expanded Voting Capital of the Target Company.
The details of the Open Offer are as follows:
| Metric | Detail |
|---|---|
| Target Company | Parmax Pharma Limited |
| Offer Price | ₹42.80 per Equity Share (payable in cash) |
| Face Value | ₹10.00 per Equity Share |
| Maximum Offer Size | 23,46,250 Shares |
| Estimated Total Consideration | ₹10,04,19,500.00 |
| Tendering Period Start Date | July 30, 2026 |
| Tendering Period End Date | August 12, 2026 |
Strategic Objective and Rationale
The Open Offer is a mandatory undertaking by the Acquirers and PACs following the proposed Underlying Transaction. The primary objective of the consortium in pursuing this transaction is to secure substantial equity holding and control over the Target Company.Following the consummation of the Underlying Transaction—which includes an agreement with Sellers for 1,152,450 Equity Shares and a subsequent Preferential Issue—the Acquirers and PACs are projected to hold approximately 94.34% of the Expanded Voting Capital of Parmax Pharma Limited (assuming full acceptance of the Open Offer). This acquisition will result in the Acquirers and PACs being classified as promoters, while the Existing Promoters will be declassified from this category.
The proposed transaction aligns with the Target Company's operations, which include research, manufacturing, and sale of active pharmaceutical ingredients (APIs) and speciality chemicals.
Current Shareholding Snapshot
Details regarding the pre-offer holdings of the Acquirers, PACs, and the public shareholders are available:| Stakeholder Category | Pre-Offer Holding | Post-Offer Projection (Assuming Full Acceptance) |
|---|---|---|
| Existing Promoters | 11,52,450 Shares (30.80%) | Will be declassified from Promoter category |
| Acquirers and PACs | 7,14,800 Shares (27.20%) | Projected at 94.34% of Expanded Voting Capital |
| Public Shareholders | Remaining shares | Expected to hold the remaining portion |
The Acquirers and PACs have committed capital and made firm financial arrangements for this acquisition, with a dedicated Escrow Account established with ICICI Bank Limited holding ₹5,20,00,000.00 in cash.
Financial Assessment and Offer Price Justification
The Offer Price of ₹42.80 per Equity Share has been determined to be higher than the following key parameters:- Acquisition Prices: The highest negotiated price for shares acquired under the SPA (₹35.00) and the Preferential Issue (₹36.50).
- Volume-Weighted Average Price (Preceding 52 weeks): ₹31.00
- Highest Acquisition Price (Preceding 26 weeks): ₹31.00
- Volume-Weighted Average Market Price (BSE, 60 days): ₹42.79
The price determination adheres to the requirements of SEBI (SAST) Regulations. The Acquirers and PACs have confirmed that they possess the necessary financial resources to fulfill all obligations related to the Open Offer.
Overview of Participants' Stake
Key figures related to the proposed acquisition by individual entities are outlined below:| Participant | Nature of Holding | Proposed Shares through Preferential Issue (Shares + Warrants) |
|---|---|---|
| Acquirer 1 (Dhiren Chandulal Shah) | Acquisition & Preferred Allotment | 6,04,190 Equity Shares / 5,35,715 Warrants |
| Acquirer 2 (Sunil Chinubhai Shah) | Acquisition & Preferred Allotment | 91,911 Equity Shares / 81,494 Warrants |
| PAC 1 (Dhairya Dhiren Shah) | Acquisition & Preferred Allotment | 1,20,838 Equity Shares / 1,07,143 Warrants |
| PAC 2 (Hiren Pravin Doshi) | Acquisition & Preferred Allotment | 2,17,508 Equity Shares / 192,857 Warrants |
| PAC 3 (Sheetal Hiren Doshi) | Acquisition & Preferred Allotment | 24,167 Equity Shares / 21,429 Warrants |
| PAC 4 (Nirmal Sunilbhai Shah) | Acquisition & Preferred Allotment | 1,64,832 Equity Shares / 1,44,715 Warrants |
| PAC 5 (Rupa Sunil Shah) | Off-market Acquisition & Preferred Allotment | 69,206 Equity Shares / 61,363 Warrants |
| PAC 6 (Vijaykumar Natvarlal Shiyani) | Acquisition & Preferred Allotment | 1,61,117 Equity Shares / 142,857 Warrants |
| PAC 7 (Kamlesh Natvarlal Shiyani) | Acquisition & Preferred Allotment | 1,61,974 Equity Shares / 1,43,286 Warrants |
| PAC 8 (Abhay Chinubhai Shah) | Off-market Acquisition & Preferred Allotment | 3,22,235 Equity Shares / 2,85,715 Warrants |
| PAC 9 (Umang Alkesh Gosalia) | Current Shareholding & Preferred Allotment | 3,42,466 Equity Shares |
| PAC 10 (Meena Alkesh Gosalia) | Current Shareholding | 4,74,800 Equity Shares |
The Open Offer is open to all public shareholders of Parmax Pharma Limited. Those tendering their shares are advised that acceptance and settlement procedures follow the guidelines set forth in the LOF.
Stock Price Movement
For Parmax Pharma Ltd as of 10:14, shares are edging higher, currently trading at ₹107.06, which represents a gain of 1.99%. However, the company's stock is locked and trading completely flat intraday, with the high and low both resting at ₹107.06.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: